After many negative trial results for non-small cell lung cancer (NSCLC) therapies for some time, the field is now evolving in a very promising direction fast. Here, Solange Peters, MD, PhD, of Lausanne University Hospital, Lausanne, France, discusses the role of immunotherapy in the radical treatment of NSCLC, following the recent publication of data from the Phase III PACIFIC study (NCT02125461) of durvalumab. Prof. Peters highlights the many combination options for immunotherapy, including that with radiotherapy. She also covers the role of chemotherapy and surgery in the context of immunotherapy. This video was recorded at the British Thoracic Oncology Group (BTOG) Annual Conference 2018, held in Dublin, Ireland.
The role of immunotherapy in the radical treatment of NSCLC: where are we headed?
